Lichenoid keratosis Trials in Disease

Study on Clobetasol, Mometasone, and Tacrolimus for Treating Vulvar Lichen Sclerosus in Children

This clinical trial is investigating three different topical ointments for treating lichen sclerosus affecting the vulvar area in children and teenagers. Lichen sclerosus is a chronic skin condition that causes patches of thin, white, wrinkled skin, primarily in the genital area. It can lead to itching, discomfort, pain, and changes in skin appearance.

Main inclusion criteria:

• Female patients aged between 2 and 18 years old
• Confirmed clinical diagnosis of vulval lichen sclerosus
• Good general health based on physical examination
• Symptoms scoring at least 1 point on the Sn-LTS scale (a measurement tool for symptom severity)
• Normal levels of certain hormones (ACTH and cortisol)
• Informed consent from a parent or legal representative (and from the patient if aged 13 or older)
• At least 2 weeks must have passed since any vaccination before starting the study medication

Main exclusion criteria:

• Male patients are not eligible
• Patients without a confirmed clinical diagnosis of vulval lichen sclerosus
• Patients outside the specified age range
• Those who do not meet the vulnerable population criteria selected for this study

Focus and goals:

The trial aims to compare the effectiveness and safety of three different topical treatments over a 12-week period. Participants will be randomly assigned to one of three treatment groups, each receiving a different ointment applied directly to the affected skin. The primary goal is to achieve at least a 75% reduction in symptoms and a 50% improvement in quality of life after 12 weeks of treatment. Researchers will also conduct a long-term evaluation 15 months after starting treatment to see if the improvements are maintained over time. The study will also look at how factors such as age, immune system function, and genetic makeup might influence how well the treatments work.

Investigational drugs:

• Clobetasol propionate (0.05%): A potent corticosteroid that works by suppressing the immune response and reducing inflammation. It helps relieve symptoms like itching and redness by decreasing the production of substances in the body that cause inflammation.
• Mometasone furoate (0.1%): Another corticosteroid medication that inhibits the release of inflammatory substances, thereby reducing swelling, itching, and irritation in the affected skin.
• Tacrolimus (0.03%): A calcineurin inhibitor and immunosuppressant that works differently from corticosteroids. It blocks the activity of certain immune cells, helping to decrease inflammation and prevent flare-ups without some of the side effects associated with long-term steroid use.

Summary

Currently, there is one active clinical trial addressing lichenoid keratosis, specifically focusing on vulvar lichen sclerosus in the pediatric population. This trial is being conducted in Poland and is evaluating three established topical medications with different mechanisms of action. The study includes both short-term assessment at 12 weeks and long-term follow-up at 15 months, providing valuable information about sustained treatment benefits. The trial's focus on comparing corticosteroids of varying potency with an immunosuppressant offers an important opportunity to identify the most effective and safest treatment option for young patients dealing with this chronic skin condition.